+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Basic and Clinical Research Against Advanced Glycation End Products (Ages): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications



Basic and Clinical Research Against Advanced Glycation End Products (Ages): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications



Recent Advances in Cardiovascular Drug Discovery (Formerly Recent Patents on Cardiovascular Drug Discovery) 10(1): 10-33




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 068067669

Download citation: RISBibTeXText

DOI: 10.2174/1574890110666151104120039


Related references

Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. Recent Advances in Cardiovascular Drug Discovery 10(1): 10-33, 2016

Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Research in Cardiovascular Medicine 4(2): E26949, 2015

Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. Medical Sciences 6(2), 2018

Fluorophores advanced glycation end products (AGEs)-to-NADH ratio is predictor for diabetic chronic kidney and cardiovascular disease. Journal of Diabetes and Its Complications 29(7): 893-897, 2016

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93-106, 2008

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proceedings of the National Academy of Sciences of the United States of America 91(16): 7742-7746, 1994

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia E Metabologia 52(6): 940-950, 2008

Advanced glycation end-products in senile diabetic and non-diabetic patients with cardiovascular complications. Age 30(4): 303-309, 2009

Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chinese Journal of Natural Medicines 14(11): 844-855, 2017

Advanced Glycation End Products (Ages) and Cardiovascular Disease (Cvd) in Diabetes. Cardiovascular & Hematological Agents in Medicinal Chemistry 5(3): 236-240, 2007

Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Cardiovascular and Hematological Agents in Medicinal Chemistry 5(3): 236-240, 2007

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology 14: 2, 2016

Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease. Cardiovascular Therapeutics 26(1): 50-58, 2008

Advanced glycation end products and diabetic cardiovascular disease. Cardiology in Review 20(4): 177-183, 2012